MedTrace Logo

A Long Term Follow-up Study of TScan TCR-T Products

NCT06976736 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-09-10

No results posted yet for this study

Summary

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.

Conditions

Interventions

OTHER

Observational

Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products

Sponsors & Collaborators

  • TScan Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michelle Matzko, MD · Medical Monitor

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-09
Primary Completion
2040-09-30
Completion
2040-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06976736 on ClinicalTrials.gov